Using statins to treat 'healthy' patients: Are we there yet?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 2, 2009, Pages 103-105

  Shah, Bijal M ^a   Kemp, Robert ^a   Clearfield, Michael ^b  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b Touro University California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEALTH CARE COST; HEALTH CARE PRACTICE; HUMAN; ISCHEMIC HEART DISEASE; TREATMENT INDICATION; VASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; COST; ECONOMICS; META ANALYSIS; PREVENTIVE MEDICINE;

CLINICAL TRIALS AS TOPIC; COHORT STUDIES; CORONARY DISEASE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS AS TOPIC; PREVENTIVE MEDICINE; PYRIMIDINES; SULFONAMIDES;

EID: 68349126024     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.5     Document Type: Editorial

References (10)

1. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359 (21), 2195-2207 (2008).
2. Grundy SM, Cleeman JI, Metz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
3. Woloshin S, Schwartz LM, Kerin K, Welch HG. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States. J. Gen. Intern. Med. 22(2), 197-204 (2007).
4. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
5. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 357(15), 1477-1486 (2007).
6. Ward S, Lloyd Jones M, Pandor A et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess. 11(14), 1-160, iii-iv (2007).
7. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 333(7579), 1145 (2006).
8. Chan KY, Boucher ES, Gandhi PJ, Silva MA. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am. J. Health Syst. Pharm. 61(16), 1676-1681 (2004).
9. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur. Heart J. 22(9), 751-761 (2001).
10. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am. J. Med. 114(6), 485-494 (2003).